{
    "General": {
        "Code": "ABBV",
        "Type": "Common Stock",
        "Name": "AbbVie Inc. CDR",
        "Exchange": "NEO",
        "CurrencyCode": "CAD",
        "CurrencyName": "Canadian Dollar",
        "CurrencySymbol": "C$",
        "CountryName": "Canada",
        "CountryISO": "CA",
        "OpenFigi": null,
        "ISIN": null,
        "LEI": null,
        "PrimaryTicker": null,
        "CIK": null,
        "EmployerIdNumber": null,
        "FiscalYearEnd": "December",
        "IPODate": null,
        "InternationalDomestic": null,
        "Sector": "Healthcare",
        "Industry": "Drug Manufacturers-General",
        "GicSector": "Health Care",
        "GicGroup": "Pharmaceuticals, Biotechnology & Life Sciences",
        "GicIndustry": "Pharmaceuticals",
        "GicSubIndustry": "Pharmaceuticals",
        "Description": "AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Beh\u00e7et's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; Genentech, Inc.; and California Institute for Biomedical Research (Calibr). The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.",
        "Address": null,
        "AddressData": null,
        "Listings": {},
        "Officers": {},
        "Phone": null,
        "WebURL": null,
        "LogoURL": "",
        "FullTimeEmployees": 50000,
        "UpdatedAt": "2023-08-27"
    },
    "Highlights": {
        "MarketCapitalization": null,
        "MarketCapitalizationMln": null,
        "EBITDA": null,
        "PERatio": null,
        "PEGRatio": null,
        "WallStreetTargetPrice": null,
        "BookValue": null,
        "DividendShare": null,
        "DividendYield": null,
        "EarningsShare": null,
        "EPSEstimateCurrentYear": 0,
        "EPSEstimateNextYear": 0,
        "EPSEstimateNextQuarter": null,
        "EPSEstimateCurrentQuarter": 0,
        "MostRecentQuarter": null,
        "ProfitMargin": 0,
        "OperatingMarginTTM": 0,
        "ReturnOnAssetsTTM": 0,
        "ReturnOnEquityTTM": 0,
        "RevenueTTM": 0,
        "RevenuePerShareTTM": 0,
        "QuarterlyRevenueGrowthYOY": 0,
        "GrossProfitTTM": 0,
        "DilutedEpsTTM": 0,
        "QuarterlyEarningsGrowthYOY": 0
    },
    "Valuation": {
        "TrailingPE": 0,
        "ForwardPE": 0,
        "PriceSalesTTM": 0,
        "PriceBookMRQ": 0,
        "EnterpriseValue": 0,
        "EnterpriseValueRevenue": 0,
        "EnterpriseValueEbitda": 0
    },
    "SharesStats": {
        "SharesOutstanding": 0,
        "SharesFloat": 0,
        "PercentInsiders": 0,
        "PercentInstitutions": 0,
        "SharesShort": null,
        "SharesShortPriorMonth": null,
        "ShortRatio": null,
        "ShortPercentOutstanding": null,
        "ShortPercentFloat": null
    },
    "Technicals": {
        "Beta": null,
        "52WeekHigh": 24.45,
        "52WeekLow": 19.45,
        "50DayMA": 0,
        "200DayMA": 0,
        "SharesShort": 0,
        "SharesShortPriorMonth": 0,
        "ShortRatio": 0,
        "ShortPercent": 0
    },
    "SplitsDividends": {
        "ForwardAnnualDividendRate": 0,
        "ForwardAnnualDividendYield": 0,
        "PayoutRatio": 0,
        "DividendDate": null,
        "ExDividendDate": null,
        "LastSplitFactor": null,
        "LastSplitDate": null,
        "NumberDividendsByYear": {
            "0": {
                "Year": 2023,
                "Count": 2
            }
        }
    },
    "Holders": null,
    "InsiderTransactions": {},
    "outstandingShares": {
        "annual": {},
        "quarterly": {}
    },
    "Earnings": {
        "History": {},
        "Trend": {},
        "Annual": {}
    },
    "Financials": {
        "Balance_Sheet": {
            "currency_symbol": null,
            "quarterly": {},
            "yearly": {}
        },
        "Cash_Flow": {
            "currency_symbol": null,
            "quarterly": {},
            "yearly": {}
        },
        "Income_Statement": {
            "currency_symbol": null,
            "quarterly": {},
            "yearly": {}
        }
    }
}